Universitätsklinikum Essen WTZ-Ambulanz, Innere Medizin (Tumorforschung)
Welcome,         Profile    Billing    Logout  
 9 Trials 
12 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Schuler, Martin
GALAXIES LUNG-201, NCT05565378 / 2021-005115-32: A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer

Recruiting
2
340
Europe, Japan, US, RoW
Pembrolizumab, Dostarlimab, GSK4057190, Belrestotug, EOS884448, GSK4428859A, Nelistotug, GSK6097608
GlaxoSmithKline, iTeos Therapeutics
Lung Cancer, Non-Small Cell
10/25
10/28
Neopredict-lung, NCT04205552 / 2019-002478-29: Neoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer Patients

Checkmark Data from NEOpredict study for resectable NSCLC
Dec 2022 - Dec 2022: Data from NEOpredict study for resectable NSCLC
Recruiting
2
90
Europe
Nivolumab 10 MG/ML Intravenous Solution, Relatlimab 10 MG/ML Intravenous Solution
University Hospital, Essen
NSCLC Stage II, NSCLC, Stage IIIA, NSCLC, Stage I
03/25
06/25
NCT05825625: NeoTRACK - Dissection of IO Efficacy in NSCLC by Longitudinal tracKing

Recruiting
2
35
Europe
Atezolizumab, Tecentriq, Tiragolumab, no other name available
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Thoraxklinik-Heidelberg gGmbH, Roche Pharma AG
Non-small Cell Lung Cancer
11/29
02/30
GDFATHER, NCT04725474 / 2020-002103-19: First-in-Human Study of the GDF-15 Neutralizing Antibody Visugromab (CTL-002) in Patients With Advanced Cancer

Active, not recruiting
1/2
274
Europe
visugromab (CTL-002)
CatalYm GmbH, CatalYm GmbH
Solid Tumor, Adult
10/25
10/27
NCT06586515: A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

Recruiting
1
530
Europe, Canada, Japan, US
LY3962673, Cetuximab, Gemcitabine, nab-paclitaxel, Oxaliplatin, leucovorin, Irinotecan, 5-fluorouracil
Eli Lilly and Company, Loxo Oncology, Inc.
Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer
03/29
03/29
DigiNet, NCT05818449: Improvement of Personalized Lung Cancer Care Through Digital Connection and Patient Participation

Active, not recruiting
N/A
850
Europe
DigiNet intervention
University of Cologne, Gemeinsamer Bundesausschuss (G-BA), AOK Rheinland/Hamburg, AOK Nordwest, BARMER, University Hospital, Essen, Charite University, Berlin, Germany, Berlin Institute of Health, Helios Klinikum Emil von Behring, University Hospital Carl Gustav Carus, Deutsche Krebsgesellschaft e.V., Berufsverband der Niedergelassenen Hämatologen und Onkologen in Deutschland e.V., AOK Bundesverband, FOM Hochschule für Oekonomie und Management, University Medicine Greifswald, Technische Universität Dresden
Non-small Cell Lung Cancer Stage IV
03/25
03/25
Kasper, Stefan
RAMTAS, NCT03520946 / 2017-004162-99: RAMucirumab in Combination Wth TAS102 vs. TAS102 Alone in Chemotherapy Refractory Metastatic Colorectal Cancer Patients

Completed
3
430
Europe
Ramucirumab, TAS 102
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Eli Lilly and Company, Trium Analysis Online GmbH
Colorectal Cancer
07/24
07/24
Ahrens, Marit
FIBROSARC, NCT04650984 / 2016-003239-38: A Study Comparing the Efficacy of L19TNF+Doxorubicin vs Doxorubicin Alone as First-line Therapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma

Recruiting
3
102
Europe
Onfekafusp alfa, L19TNF, Doxorubicin
Philogen S.p.A.
Soft Tissue Sarcoma
12/25
12/25
TRABTRAP, NCT05597917 / 2020-005858-21: tTF-NGR Randomized Study - STS

Recruiting
3
126
Europe
Trabectedin, Yondelis, tTF-NGR
Universität Münster, Anturec Pharmaceuticals GmbH
Soft Tissue Sarcoma
12/25
12/26
PROTraSarc, NCT06050434: Prospective Study to Evaluate Patient Reported Outcomes (PRO) During Rechallenge With Trabectedin in Sarcoma Patients

Completed
N/A
7
Europe
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, PharmaMar
Soft Tissue Sarcoma
07/24
07/24
Tometten, Mareike
NPC-Nivo, NCT06019130: Nivolumab in Children and Adults With Nasopharyngeal Carcinoma

Recruiting
2
57
Europe
Nivolumab, Opdivo, Cisplatin, Cisplatin Teva, 5-Fluorouracil, Fluorouracil-GRY, Gemcitabine, Gemcitabin-GRY, Radiotherapy, Interferon beta-1a, Rebif, MRI, PET, Patient-Reported Outcomes
German Society for Pediatric Oncology and Hematology GPOH gGmbH, Deutsche Krebshilfe e.V., Bonn (Germany)
Nasopharyngeal Carcinoma, Nasopharyngeal Cancer, Nasopharyngeal Neoplasms, Nasopharynx Cancer
01/26
01/28
NCT06062420: A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202

Recruiting
2
360
Europe, Canada, Japan, US, RoW
Dostarlimab, Belrestotug, Nelistotug, GSK4381562
GlaxoSmithKline, iTeos Therapeutics
Neoplasms, Head and Neck
05/27
05/27

Download Options